Moleculin Biotech, INC 8-K filings

Moleculin Biotech has announced plans to proceed with a Phase 3 clinical trial for Annamycin in combination with cytarabine for relapsed or refractory AML, following a positive meeting with the FDA.

Moleculin Biotech has completed its End of Phase 2 meeting with the FDA regarding its Annamycin clinical trial for AML, with positive remission rates reported.

Moleculin Biotech released a new corporate presentation on June 18, 2024, providing an update on the company's activities.

Moleculin Biotech reports encouraging preliminary results from its Phase 1B/2 trial of Annamycin in combination with Cytarabine for acute myeloid leukemia (AML), showing significant efficacy and no cardiotoxicity.

Moleculin Biotech's abstract on Liposomal Annamycin for acute myeloid leukemia treatment has been accepted for a poster presentation at the European Hematology Association 2024 Hybrid Congress.

Moleculin Biotech has commenced a Phase 2 clinical trial, funded by the NIH, to evaluate WP1066 in combination with radiation therapy for the treatment of glioblastoma.

Moleculin Biotech, Inc. has released a new corporate presentation, which is available on the company's website.

Moleculin Biotech reports promising interim clinical trial results for Annamycin in acute myeloid leukemia (AML) and provides a financial update for the first quarter of 2024.

Moleculin Biotech reports promising interim clinical data for Annamycin in AML and provides a financial update for the first quarter of 2024.

Moleculin Biotech has received a patent issue notification for its liposomal Annamycin delivery technology, which is expected to provide composition protection until 2040.

Moleculin Biotech will release its first quarter 2024 financial results on May 10, 2024, followed by a conference call on May 13, 2024, to discuss the results.

Moleculin Biotech released a new corporate presentation on May 7, 2024, providing an update on the company's activities.

Moleculin Biotech reports promising interim results for Annamycin in treating acute myeloid leukemia (AML), showing a 62% composite complete remission rate in 1st and 2nd line patients.

Moleculin Biotech will host a virtual AML Clinical Day on May 7, 2024, featuring Dr. Martin S. Tallman, to discuss the company's AML clinical development program and Annamycin.

Moleculin Biotech released a new corporate presentation on April 25, 2024, which is now available on their website.

Moleculin Biotech has been granted Orphan Drug Designation by the European Medicines Agency for Annamycin in the treatment of Acute Myeloid Leukemia (AML).

Moleculin Biotech's Annamycin shows promising preclinical results, demonstrating high anti-cancer activity and a lack of cardiotoxicity, potentially expanding its use in cancer treatment.

Moleculin Biotech has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed at or above $1.00 for ten consecutive business days.

Moleculin Biotech has received a patent issue notification for its Annamycin drug, a next-generation anthracycline targeting acute myeloid leukemia (AML), with patent protection extending to 2040.

Moleculin Biotech released a new corporate presentation on March 25, 2024, which is now available on their website.

Moleculin Biotech reports positive interim results from its Phase 1B/2 trial of Annamycin in combination with Cytarabine (AnnAraC) for second-line Acute Myeloid Leukemia (AML), demonstrating a 60% complete response composite (CRc) rate.

Moleculin Biotech announced its full year 2023 financial results, highlighting positive clinical data for Annamycin and a recent capital raise extending their cash runway into the fourth quarter of 2024.

Moleculin Biotech will release its 2023 financial results on March 22, 2024, and host a conference call on March 25, 2024, to discuss these results and provide a clinical update on Annamycin.

Moleculin Biotech has announced a 1-for-15 reverse stock split of its common stock, effective March 21, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Moleculin Biotech is pursuing an accelerated approval pathway for Annamycin in relapsed and refractory AML, aiming for a pivotal trial by year-end and potential market entry within 18 months.

Moleculin Biotech's CEO discussed Annamycin's potential to significantly improve outcomes for second-line AML patients, potentially tripling the number of patients achieving complete remission.

Moleculin Biotech's CEO, Walter Klemp, discussed the significant progress of their drug candidate Annamycin in treating relapsed or refractory Acute Myeloid Leukemia (AML) during a virtual investor call.

Moleculin Biotech, Inc. has released a new corporate presentation, which is available on the company's website.

Moleculin Biotech's stockholders approved the issuance of shares related to warrants and an adjournment proposal at a special meeting held on February 14, 2024.

Moleculin Biotech reports encouraging preliminary data from its Annamycin clinical trials and sets expectations for multiple data readouts and a transition to pivotal Phase 2B/3 studies in 2024.